Windtree signs sourcing deal for Evofem's FDA-approved PHEXXI contraceptive gel

WINDTREE THERAPEUTICS INC /DE/

License and Supply Agreement makes Windtree sourcing partner for Evofem's PHEXXI (hormone-free vaginal gel).
PHEXXI generated >$19M revenue in FY2024; 96,000 boxes of 12 applicators sold.
Windtree aims to cut manufacturing costs via its contacts, aiding Evofem's global expansion.
Saundra Pelletier is CEO of Evofem and also serves on Windtree's board of directors.
Deal is first step in Windtree's new strategy to become a revenue-generating biotech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.